BerGenBio Announces Final Bemcentinib Phase 2 Data in AML and MDS Presented at the 2023 ASH Meeting
· Bemcentinib is an oral highly selective AXL inhibitor in development for cancer and severe respiratory infections · Final Phase 2 data indicates a favorable safety profile with promising efficacy in AML and MDS patients BERGEN, Norway, December 11, 2023, – BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, today announced that a poster highlighting final results from a Phase 2 clinical study of its highly selective AXL inhibitor bemcentinib in patients with Acute Myeloid